TY - JOUR
T1 - The successful uptake and sustainability of rapid infectious disease and antimicrobial resistance point-of-care testing requires a complex ‘mix-and-match’ implementation package
AU - on behalf of the JPIAMR AMR-RDT consortium
AU - Hays, John P.
AU - Mitsakakis, Konstantinos
AU - Luz, Saturnino
AU - van Belkum, Alex
AU - Becker, Karsten
AU - van den Bruel, Ann
AU - Harbarth, Stephan
AU - Rex, John H.
AU - Simonsen, Gunnar Skov
AU - Werner, Guido
AU - Di Gregori, Valentina
AU - Lüdke, Gerd
AU - van Staa, Tjeerd
AU - Moran-Gilad, Jacob
AU - Bachmann, Till T.
N1 - Funding Information:
Funding information The publication was made possible by a grant from the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), which was awarded to the JPIAMR Transnational Working Group Antimicrobial Resistance - Rapid Diagnostic Tests (JPIAMRWG-020).
Funding Information:
Declaration of interests JPH, KM, SL and TTB are infectious disease academic/diagnostic innovators. AvB is a bioMérieux employee. BioMérieux develops and markets tests in the PoCT domain, but has had no influence on the current more personal account presented in this manuscript. VDG is a public health operator working as medical director, researcher and educator for public and private companies, and has no economic interests in this publication. KB is inventor of pending patents related to infectious disease diagnostics and received grants, honoraria and travel support from the EU/INTERREG, the German Federal Ministry of Education and Research and the Federal Ministry for Economic Affairs, the Netherlands Research Council for Applied and Technical Sciences as well as from Becton Dickinson, bioMérieux, Bruker Daltonik, Hain Lifescience, Roche Molecular Systems, ThermoFisher; outside the submitted work. JHR is Chief Medical Officer & Director, F2G, Ltd.; Non-Executive Director & Consultant, Adenium Biotech ApS; Operating Partner & Consultant, Advent Life Sciences; and Expert-in-Residence, Wellcome Trust; He sits on the scientific advisory boards of Macrolide Pharmaceuticals; Bugworks Research, Inc.; Basilea Pharmaceutica; Forge Therapeutics, Inc.; and Novo Holdings; He is a shareholder in AstraZeneca Pharmaceuticals; F2G, Ltd.; Adenium Biotech ApS; Advent Life Sciences; Macrolide Pharmaceuticals; and Bugworks Research, Inc.; He has received consulting fees from Phico Therapeutics; ABAC Therapeutics; Polyphor, Ltd.; Heptares Therapeutics, Ltd.; Gangagen, Ltd.; Meiji Seika Pharma; Basilea Pharmaceutica International Ltd.; Allecra Therapeutics GmbH; Forge Therapeutics, Inc.; SinSa Labs; AtoxBio; Peptilogics; F. Hoffmann-LaRoche, Ltd.; and Novo Holdings. GL is a Curetis employee. Curetis develops and markets molecular tests for determination of pathogens and resistances but has had no influence on the current more personal account presented in this manuscript. AvdB, SH, GSS, GW, J M-G and TvS have no interests to declare.
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/6/1
Y1 - 2019/6/1
N2 - The emergence and spread of antimicrobial resistance is one of the major global issues currently threatening the health and wealth of nations, with effective guidelines and intervention strategies urgently required. Such guidelines and interventions should ideally be targeted at individuals, communities, and nations, requiring international coordination for maximum effect. In this respect, the European Joint Programming Initiative on Antimicrobial Resistance Transnational Working Group ‘Antimicrobial Resistance - Rapid Diagnostic Tests’ (JPIAMR AMR-RDT) is proposing to consider a ‘mix-and-match’ package for the implementation of point-of-care testing (PoCT), which is described in this publication. The working group was established with the remit of identifying barriers and solutions to the development and implementation of rapid infectious disease PoCT for combatting the global spread of antimicrobial resistance. It constitutes a multi-sectoral collaboration between medical, technological, and industrial opinion leaders involved in in vitro diagnostics development, medical microbiology, and clinical infectious diseases. The mix-and-match implementation package is designed to encourage the implementation of rapid infectious disease and antimicrobial resistance PoCT in transnational medical environments for use in the fight against increasing antimicrobial resistance.
AB - The emergence and spread of antimicrobial resistance is one of the major global issues currently threatening the health and wealth of nations, with effective guidelines and intervention strategies urgently required. Such guidelines and interventions should ideally be targeted at individuals, communities, and nations, requiring international coordination for maximum effect. In this respect, the European Joint Programming Initiative on Antimicrobial Resistance Transnational Working Group ‘Antimicrobial Resistance - Rapid Diagnostic Tests’ (JPIAMR AMR-RDT) is proposing to consider a ‘mix-and-match’ package for the implementation of point-of-care testing (PoCT), which is described in this publication. The working group was established with the remit of identifying barriers and solutions to the development and implementation of rapid infectious disease PoCT for combatting the global spread of antimicrobial resistance. It constitutes a multi-sectoral collaboration between medical, technological, and industrial opinion leaders involved in in vitro diagnostics development, medical microbiology, and clinical infectious diseases. The mix-and-match implementation package is designed to encourage the implementation of rapid infectious disease and antimicrobial resistance PoCT in transnational medical environments for use in the fight against increasing antimicrobial resistance.
KW - Diagnostic innovator
KW - Future proofing
KW - General public
KW - Healthcare providers
KW - Implementation package
KW - Infectious diseases antimicrobial resistance
KW - Point-of-care testing
UR - http://www.scopus.com/inward/record.url?scp=85061012441&partnerID=8YFLogxK
U2 - 10.1007/s10096-019-03492-4
DO - 10.1007/s10096-019-03492-4
M3 - Review article
C2 - 30710202
AN - SCOPUS:85061012441
SN - 0934-9723
VL - 38
SP - 1015
EP - 1022
JO - European Journal of Clinical Microbiology and Infectious Diseases
JF - European Journal of Clinical Microbiology and Infectious Diseases
IS - 6
ER -